Neonc Technologies Holdings, Inc.
NTHI
NASDAQ·Healthcare·Biotechnology·Mkt cap $130.4M
$5.03
▲ +5.01%
P/E
-2.27
Mkt Cap
$130.4M
52-Wk Range
$3.01–$12.99
52-Week Range
$3.01 - $12.99
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 39.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary molecular delivery technology for CNS drug targeting
- Novel approach to blood-brain barrier penetration
- Early-stage pipeline with differentiated product candidates
- Strategic positioning in high-value oncology market
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Stable outlook
Clinical trial advancement of NEO100 for glioblastoma
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+13.8% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying NTHI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 14, 2026
Reported EPS of -$0.58 vs -$0.12 consensus (-397.1% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-397.1%
Revenue trend · last 6Q
—
—
—
—
-100%
—
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$40.0K
$0
$0
$0
$0
$0
Margins · last 6Q
Gross
—
Profit
—
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: BTIG · May 26, 2026
vs Industry
How NTHI stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.